Stephanie Smith–Marrone

427 total citations
13 papers, 291 citations indexed

About

Stephanie Smith–Marrone is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Otorhinolaryngology. According to data from OpenAlex, Stephanie Smith–Marrone has authored 13 papers receiving a total of 291 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Pulmonary and Respiratory Medicine, 7 papers in Oncology and 6 papers in Otorhinolaryngology. Recurrent topics in Stephanie Smith–Marrone's work include Lung Cancer Treatments and Mutations (7 papers), Head and Neck Cancer Studies (6 papers) and Brain Metastases and Treatment (3 papers). Stephanie Smith–Marrone is often cited by papers focused on Lung Cancer Treatments and Mutations (7 papers), Head and Neck Cancer Studies (6 papers) and Brain Metastases and Treatment (3 papers). Stephanie Smith–Marrone collaborates with scholars based in United States and South Korea. Stephanie Smith–Marrone's co-authors include Eric J. Sherman, David G. Pfister, M. Catherine Pietanza, Mark G. Kris, Matthew G. Fury, Camelia S. Sima, John J. Fiore, Shrujal S. Baxi, Gregory J. Riely and Sofia Haque and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and Journal of Thoracic Oncology.

In The Last Decade

Stephanie Smith–Marrone

13 papers receiving 288 citations

Peers

Stephanie Smith–Marrone

ONCOL

PRM

EPIDE

OTORH

Alesha A. Thai Australia

S Whelan France

Gunjesh Kumar Singh India

Yousri Rostom Egypt

D. Spielsinger United States

María José Lecumberri Spain

Felix Ho United States

Brij Sood United States

Huiqiang Huang China

Alesha A. Thai Australia

Stephanie Smith–Marrone

230 ×1.1

ONCOL

92 ×0.8

PRM

71 ×0.7

EPIDE

64 ×0.9

OTORH

55 ×1.5

Citations per year, relative to Stephanie Smith–Marrone Stephanie Smith–Marrone (= 1×) peers Alesha A. Thai

Countries citing papers authored by Stephanie Smith–Marrone

Since Specialization

Citations

This map shows the geographic impact of Stephanie Smith–Marrone's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stephanie Smith–Marrone with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stephanie Smith–Marrone more than expected).

Fields of papers citing papers by Stephanie Smith–Marrone

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stephanie Smith–Marrone. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stephanie Smith–Marrone. The network helps show where Stephanie Smith–Marrone may publish in the future.

Co-authorship network of co-authors of Stephanie Smith–Marrone

This figure shows the co-authorship network connecting the top 25 collaborators of Stephanie Smith–Marrone. A scholar is included among the top collaborators of Stephanie Smith–Marrone based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stephanie Smith–Marrone. Stephanie Smith–Marrone is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

13 of 13 papers shown

Shu, Catherine A., Claud Grigg, Codruța Chiuzan, et al.. (2018). Neoadjuvant atezolizumab + chemotherapy in resectable non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology. 36(15_suppl). 8532–8532. 31 indexed citations

Pietanza, M. Catherine, Matthew D. Hellmann, John J. Fiore, et al.. (2016). Phase II Study of a Non-Platinum–Containing Doublet of Paclitaxel and Pemetrexed with Bevacizumab as Initial Therapy for Patients with Advanced Lung Adenocarcinomas. Journal of Thoracic Oncology. 11(6). 890–899. 2 indexed citations

Baxi, Shrujal S., Talya Salz, Han Xiao, et al.. (2016). Employment and return to work following chemoradiation in patient with HPV-related oropharyngeal cancer. PubMed. 1(1). 4–4. 29 indexed citations

Naidoo, Jarushka, Tunç Iyriboz, Kaitlin M. Woo, et al.. (2016). Large Cell Neuroendocrine Carcinoma of the Lung: Clinico-Pathologic Features, Treatment, and Outcomes. Clinical Lung Cancer. 17(5). e121–e129. 105 indexed citations

Riely, Gregory J., Helena A. Yu, Dennis Stephens, et al.. (2015). A phase 1 study of crizotinib and ganetespib (STA-9090) in ALK positive lung cancers.. Journal of Clinical Oncology. 33(15_suppl). 8064–8064. 10 indexed citations

Fury, Matthew G., Han Xiao, Eric J. Sherman, et al.. (2015). Phase II trial of bevacizumab + cetuximab + cisplatin with concurrent intensity‐modulated radiation therapy for patients with stage III/IVB head and neck squamous cell carcinoma. Head & Neck. 38(S1). E566–70. 29 indexed citations

McNiff, Jennifer M., et al.. (2015). Revision of immunosuppression in a solid organ transplant recipient leads to complete remission of metastatic undifferentiated carcinoma. JAAD Case Reports. 1(6). S8–S11. 2 indexed citations

Fury, Matthew G., Eric J. Sherman, Stephanie Smith–Marrone, et al.. (2014). Phase I study of weekly nab-paclitaxel + weekly cetuximab + intensity-modulated radiation therapy (IMRT) in patients with stage III–IVB head and neck squamous cell carcinoma (HNSCC). Annals of Oncology. 25(3). 689–694. 22 indexed citations

Fury, Matthew G., Han Xiao, Shrujal S. Baxi, et al.. (2014). A phase II trial of temsirolimus plus low-dose weekly carboplatin and paclitaxel for recurrent/metastatic HNSCC.. Journal of Clinical Oncology. 32(15_suppl). 6019–6019. 7 indexed citations

10.

Fury, Matthew G., Eric J. Sherman, Shyam Rao, et al.. (2013). Phase I study of weekly albumin-bound paclitaxel (ab-P) plus weekly cetuximab (Cet) plus intensity-modulated radiation therapy (IMRT) in patients with stage III/IVb head and neck squamous cell carcinoma (HNSCC).. Journal of Clinical Oncology. 31(15_suppl). 6034–6034. 1 indexed citations

11.

Fury, Matthew G., Eric J. Sherman, Neeraj Agarwal, et al.. (2012). A Randomized Phase II Study of Cetuximab Every 2 Weeks at Either 500 or 750 mg/m²for Patients With Recurrent or Metastatic Head and Neck Squamous Cell Cancer. Journal of the National Comprehensive Cancer Network. 10(11). 1391–1398. 34 indexed citations

12.

Sherman, Eric J., Alan L. Ho, Matthew G. Fury, et al.. (2012). A phase II study of temsirolimus/sorafenib in patients with radioactive iodine (RAI)-refractory thyroid carcinoma.. Journal of Clinical Oncology. 30(15_suppl). 5514–5514. 16 indexed citations

13.

Fury, Matthew G., Eric J. Sherman, Kenneth M. Algazy, et al.. (2011). A randomized phase II study of cetuximab (C) every 2 weeks at either 500 or 750 mg/m² for patients (Pts) with recurrent or metastatic (R/M) head and neck squamous cell cancer (HNSCC).. Journal of Clinical Oncology. 29(15_suppl). 5563–5563. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact